Search for 'Provider:Clinical Cancer Research,'

First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma.

By Sepúlveda Sánchez, Juan Manuel. Clinical cancer research : an official journal of the American Association for Cancer Research, 2015 . 21(3):553-60. , Formato Vancouver: Rodon J, Carducci MA, Sepulveda Sánchez JM, Azaro A, Calvo E, Seoane J et al. First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma. Clin Cancer Res. 2015 Feb 1;21(3):553-60.

Place Hold on First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma.

NIK Controls Classical and Alternative NF-kappa B Activation and Is Necessary for the Survival of Human T-cell Lymphoma Cells.

By Ortiz Romero, Pablo Luis. Clinical Cancer Research, 2013 . 19(9):2319-30. , Formato Vancouver: Odqvist L, Sánchez-Beato M, Montes-Moreno S, Martín-Sánchez E, Pajares R, Sánchez-Verde L et al. NIK controls classical and alternative NF-κB activation and is necessary for the survival of human T-cell lymphoma cells. Clin Cancer Res. 2013 May 1;19(9):2319-30.

Place Hold on NIK Controls Classical and Alternative NF-kappa B Activation and Is Necessary for the Survival of Human T-cell Lymphoma Cells.

Multiple Myeloma Patients Have a Specific Serum Metabolomic Profile That Changes after Achieving Complete Remission.

By Lahuerta Palacios, Juan José | Martínez López, Joaquín. Clinical Cancer Research, 2013 . 19(17):4770-9. , Formato Vancouver: Puchades-Carrasco L, Lecumberri R, Martínez-López J, Lahuerta JJ, Mateos MV, Prósper F et al. Multiple myeloma patients have a specific serum metabolomic profile that changes after achieving complete remission. Clin Cancer Res. 2013 Sep 1;19(17):4770-9.

Place Hold on Multiple Myeloma Patients Have a Specific Serum Metabolomic Profile That Changes after Achieving Complete Remission.

Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma.

By Castellano, Daniel | López Martín, José Antonio. Clinical Cancer Research, 2013 . 19(5):1257-68. , Formato Vancouver: Angevin E, López-Martin JA, Lin CC, Gschwend JE, Harzstark A, Castellano D et al. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clin Cancer Res. 2013 Mar;19(5):1257-68.

Place Hold on Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma.

Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure.

By Paz-Ares Rodríguez, Luis. Clinical Cancer Research, 2012 . 18(11):3170-9. , Formato Vancouver: Demetri GD, Garrett CR, Schöffski P, Shah MH, Verweij J, Leyvraz S, et al. Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. Clin Cancer Res. 2012 Jun 1;18(11):3170-9.

Place Hold on Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure.

A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors

By López Martín, José Antonio. Clinical Cancer Research, 2011 . 17(19):6313-6321. , Formato Vancouver: Tabernero J, Dirix L, Schöffski P, Cervantes A, Lopez-Martin JA, Capdevila J, et al. A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors. Clin Cancer Res. 2011;17(19):6313-21.

Place Hold on A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors